Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Pentoxifylline (anti-tumor necrosis factor drug): Effective adjuvant therapy in the control of ocular cicatricial pemphigoid
European Journal of Ophthalmology, Volume 21, No. 5, Year 2011
Notification
URL copied to clipboard!
Description
Purpose. The detection of tumor necrosis factor-α (TNF-α) in conjunctiva affected by ocular cicatricial pemphigoid (OCP) may indicate that this cytokine plays an important role in its pathogenesis. The purpose of this randomized, controlled, comparative, blinded study was to evaluate the effectiveness of adding pentoxifylline as an anti-TNF-α drug to the well-documented therapy of steroids and cyclophosphamide in controlling OCP. Methods. Thirty patients with different grades of OCP were included. They were randomly divided into 2 equal groups. Group A patients received pulse steroid and cyclophosphamide therapy; in addition, group B patients received intravenous pentoxifylline. Patients were evaluated before and after therapy clinically, histopathologically, and serologically (serum level of TNF-α). Twenty controls were included to compare their serum TNF-α level with that measured in patients with OCP. Results. Group B patients showed a more significant improvement in their clinical and histopathologic evaluation. The serum TNF-α was significantly higher in OCP cases prior to therapy compared to the control group (p=0.0001). Following therapy, serum TNF-α showed a more significant reduction in group B patients (77.4±26.1 to 19.2±15.6) compared to group A patients (50.3±14.3 to 36.2±18.3). Conclusions. The significantly increased level of serum TNF-α in OCP as compared to controls proves that TNF-α has an important role in the pathogenesis of this disease. The study illustrates that the addition of pentoxifylline to pulse steroid cyclophosphamide therapy is an effective, safe, and economical method in controlling OCP through directly reducing TNF-α levels, with long periods of remission as detected in our 18-month follow-up period. © 2011 Wichtig Editore.
Authors & Co-Authors
EL DAROUTI, MOHAMED A.
Egypt, Cairo
Cairo University Hospitals
Fakhry, Mohamed A.
Egypt, Cairo
Cairo University Hospitals
Egypt, Giza
Cairo University
Hegazy, Rehab Aly
Egypt, Cairo
Cairo University Hospitals
Hafez, Dalia A.
Egypt, Cairo
Cairo University Hospitals
Gawdat, Heba Ismail
Egypt, Cairo
Cairo University Hospitals
Statistics
Citations: 19
Authors: 5
Affiliations: 2
Identifiers
Doi:
10.5301/EJO.2011.6294
ISSN:
11206721
Research Areas
Cancer
Study Design
Randomised Control Trial
Cohort Study